7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3 Puritas >99.0% (HPLC)
Ruifu Chemical Supple intermedia de Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
acetaldehyda Diethyl acetalis CAS 3616-56-6
trans-4-dimethylaminocrotonic Acidum hydrochloridum CAS 848133-35-75
Diethylphosphonoaceticum acidum CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl) -7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Nomen chemicum | 7-Fluoro-6-Nitroquinazolin-4(1H)-one |
Synonyma | 7-Fluoro-6-Nitroquinazolin-4(3H)-one;7-Fluoro-4-Hydroxy-6-Nitroquinazoline;7-Fluoro-6-Nitroquinazolin-4-ol;7-Fluoro-6-Nitro-4-Hydroxyquinazoline;7-Fluoro-6-Nitro-1H-Quinazolin-4-one |
CAS Number | 162012-69-3 |
CATTUS Number | RF-PI2025 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C8H4FN3O3 |
M. Pondus | 209.13 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Yellow vel rufo flavo Crystal aut pulveris |
1 H NMR Spectrum | Congruunt cum Structure |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Damnum in Siccatio | <0.50% |
Totalis immunditias | <1.00% |
Proton NMR Spectrum | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Afatinib Dimaleate (CAS: 850140-73-7) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
7-Fluoro-6-Nitroquinazolin-4(1H)-unum (CAS: 162012-69-3) medium est Afatinib Dimaleate (CAS: 850140-73-7).Afatinib irreversibilis est familia interclusorum ErbB qui informationes transmissionis supprimunt et vias maiores impeditas quae in incremento et divisione cellae cancri implicantur.Quia ErbB familiae informationes transductionis mechanismi possunt per plures homodimersos et heterodimeros Urguere, simultanea inhibitio plurium membrorum familiarium ErbB (ut EGFR, HER2, ErbB3 et ErbB4) efficaciter interrumpens informationes transductionem amni possunt.Afatinib est medicamentum approbatum ad tractationem carcinomatis pulmonis non parvae cellulae (NSCLC), a Boehringer Ingelheim evoluta.Agit angiokinase inhibitor.Sicut lapatinib et neratinib, afatinib est tyrosinus kinasus inhibitor (TKI) qui etiam irrevocabiliter vetat factorem 2 (Her2) et factor incrementi epidermalis receptor 2 (Her2) et kinases receptae incrementi epidermalis.Afatinib non solum activa contra mutationes EGFR iaculis a generatione prima TKIs likeerlotinib vel gefitinib, sed etiam contra illas therapias normas non sensitivas.Propter additam actionem contra Her2, investigatur pro carcinomate pectoris necnon aliis EGFR et Her2 carcinomata agitata.